2024 UCSF-UCLA PSMA Conference Videos

Patient Selection for Radioligand Therapy: Case Study Discussion - Amir Iravani & Evan Yu

Operationalizing and Coordinating Lutetium-177 PSMA Treatment: Roles of a Multidisciplinary Prostate Cancer Team - Kristen Davis & Sarah Yenser Wood

Current Perspectives: Theranostic Targets in Prostate Cancer - Hans David Ulmert

Role of Radium-223 in the Setting of PSMA "Presentation" - Oliver Sartor

Portfolio of Alpha and Beta Emitters to Improve Outcomes Presentation - Matthias Eiber

Lutetium-177 PSMA Radioligand Therapy for Advanced Prostate Cancer: Reviewing the Pivotal VISION and TheraP Trials - Michael Morris

Workflow Considerations from the Front Desk to Nursing Including the Supportive Care Idea: The UCLA/UCSF Experience "Presentation" - Linda Gardner & Amanda Morley

PSMA-Directed Radioligand Therapy in Combination with Immunotherapy "Presentation" - Rahul Aggarwal

Therapy Resistance and Combination Therapies "Presentation" - Johannes Czernin

Evaluation of Theranostic Prostate Cancer Targets with Antibody Based Radiopharmaceuticals “Presentation” - Robert Flavell

Role of Quantitative Dosimetry "Presentation" - Carlos Uribe

Treatment Landscape of mCRPC "Presentation" - Matthew Rettig

The PSMA and Androgen Receptors in Prostate Cancer "Presentation" - Louise Emmett

SPECT Imaging Response with PSMA Radionuclide Therapy "Presentation" - Louise Emmett

What is the Optimal Time for PSMA Radioligand Therapy? "Presentation" - Oliver Sartor

Imaging Response to PSMA Radiopharmaceutical Therapy "Presentation" - Jeremie Calais

Trials Evaluating the Impact of PSMA PET on Management and Outcomes “Presentation” - Amar Kishan

Role of PSMA PET in CRPC Patients "Presentation" - Wolfgang Fendler

PSMA PET Selection of Patients for PSMA Radiopharmaceutical Therapy “Presentation” - Jeremie Calais

PSMAFore, SPLASH and ECLIPSE: Are They Different? "Presentation" - Thomas Hope, Michael Morris, & Oliver Sartor

Role of MDT in BCR: Oligometastatic Disease "Presentation" - Amar Kishan

PSMA PET Standardized Reporting "Presentation" - Matthias Eiber

PSMA PET Appropriate Use Criteria "Presentation" - Michael Morris

PSMA and RLT: The VISION and TheraP Trials "Presentation" - Michael Morris

Clinical Impact of PSMA PET Prior to Prostatectomy “Presentation” - Robert Reiter

PSMA-Targeted Radionuclide Therapy in the Pre- and Post-Chemotherapy Settings in Prostate Cancer - Louise Emmett

Incorporating PSMA PET Into Radiotherapy Planning: Impact on Definitive Therapy "Presentation" - Nicholas Nickols

ProPSMA Versus PreRP: Value of the Prospective Literature “Presentation” - Thomas Hope

Patient Selection for PSMA Radioligand Therapy - Ephraim Parent

Advancing Prostate Cancer Surgery with PSMA Imaging and Fluorescent Guidance "Presentation" - Peter Carroll

PSMA PET & The Impact of the PRIMARY Trial "Presentation" - Louise Emmett

Distinguishing True and False Positives on PSMA PET Scans "Presentation" - Courtney Lawhn Heath

Examining Differences Between PSMA PET Imaging Agents "Presentation" - Wolfgang Fendler

PSMA Targeted Imaging and Therapy in Prostate Cancer "Presentation" - Robert Flavell

Access to Cutting-Edge Therapies and Clinical Trials in the VA- Matthew Rettig

Radioligand Therapy's Role in Treating mCRPC - Oliver Sartor

Highlights: UCLA/UCSF Inaugural PSMA PET and RLT Conference - Jeremie Calais

PSMA PET and Radioligand Therapy: A Comprehensive Two-Day Conference by UCLA and UCSF - Jeremie Calais & Thomas Hope